Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 0.52 |
| ▸ | PPARA | Q07869 | 15/20 | 0.52 |
| ▸ | PPARD | Q03181 | 5/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6966781 | 1.00 | PPARG (0.52) | PPARGPPARAPPARDKCNH2PTPN1 | |
| SCHEMBL5622684 | 0.89 | PPARG (0.56) | PPARGPPARAPPARDKCNH2 | |
| SCHEMBL5622683 | 0.89 | PPARG (0.56) | PPARGPPARAPPARDKCNH2 | |
| SCHEMBL10364971 | 0.84 | HPGD (0.61) | PPARGPPARAHPGD | |
| SCHEMBL10364994 | 0.84 | HPGD (0.61) | PPARGPPARAHPGD | |
| SCHEMBL10366704 | 0.84 | HPGD (0.61) | PPARGPPARAHPGD | |
| SCHEMBL8133138 | 0.83 | PPARG (0.57) | PPARGPPARA | |
| SCHEMBL8133136 | 0.83 | PPARG (0.57) | PPARGPPARA | |
| SCHEMBL5761650 | 0.81 | PPARG (0.62) | PPARGPPARAPPARDPTPN1 | |
| SCHEMBL7617150 | 0.81 | PPARG (0.47) | PPARGPPARAPPARDHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0970077-B1 | IMPROVED METHOD FOR PRODUCING THIAZOLIDINEDIONES, AND NEW THIAZOLIDINEDIONES | ROCHE DIAGNOSTICS GMBH (DE) | 2003-05-14 | — | — | EP | disclosed |
| US-6441185-B2 | REDUCTION OF AN UNSATURATED THIAZOLIDINE-2,4-DIONE DERIVATIVE WITH METALLIC ALUMINUM IN A PROTIC SOLVENT; PURITY; ANTIDIABETIC AGENTS | ROCHE DIAGNOSTICS GMBH (DE) | 2002-08-27 | — | — | US | disclosed |
| US-20010008902-A1 | Method for producing thiazolidinediones, and new thiazolidinediones | KUHNLE HANS-FRIEDER (DE) | 2001-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008902-A1 | Method for producing thiazolidinediones, and new thiazolidinediones | NR4A1, NR2C2, NR5A2 | PPARG 39/4885PPARA 30/4885PPARD 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.